A Phase 1 randomized, double-blind, placebo-controlled, multiple ascending assessing PHA-121 I healthy volunteers
Latest Information Update: 14 Jul 2021
At a glance
- Drugs Deucrictibant (Primary)
- Indications Hereditary angioedema
- Focus Adverse reactions
- Sponsors Pharvaris
- 09 Jul 2021 According to Pharvaris media release, results from this trial were presented at the European Academy of Allergy and Clinical Immunology (EAACI) Annual Congress 2021.
- 09 Jul 2021 Results published in the Pharvaris Media Release.
- 01 Jul 2021 According to Pharvaris media release, data from this study will be presented as an e-Poster at the upcoming European Academy of Allergy and Clinical Immunology (EAACI) Annual Congress 2021.